Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK): Three Ways Big Pharma Is Seizing This Rare Opportunity

Making money in business typically happens in one of two ways. You either sell a relatively low-cost product to a large number of customers. The other option is to sell a high-cost product to a small number of customers.

Eli Lilly & Co (LLY)

After years of going with the former approach, big pharma knows that to succeed in the future requires more of the latter. That’s why several major pharmaceutical companies have been building up their capabilities to tackle the red-hot market for drugs that treat orphan diseases affecting small numbers of patients. Here are three ways that the large drugmakers are seizing this “rare” opportunity.

1. The old-fashioned way
Several companies started from scratch by researching and developing drugs for orphan diseases. Eli Lilly & Co. (NYSE:LLY) actually began this process years ago. The company received approval from the Food and Drug Administration for Alimta in 2004. Alimta became the first drug approved in the U.S. for treating malignant pleural mesothelioma, a rare form of cancer with only around 2,000 new diagnoses each year.Lilly has experienced tremendous success with Alimta, which generated nearly $2.6 billion in sales last year

Sometimes drugs that originally focus on more common diseases can also help address orphan diseases. Eli Lilly & Co. (NYSE:LLY)’s tabalumab, for example, is farthest along in development as a treatment for lupus. A phase 3 clinical study is currently under way with the drug targeting this disease. However, tabalumab was also designated by the FDA late last year as an orphan drug for treating multiple myeloma and is in a phase 2 trial for the more rare indication.

2. Making a big deal
Another approach for big pharmaceutical firms seeking to profit from the orphan drug market is to strike a big deal with a company that has products already far along in the pipeline. Merck & Co., Inc. (NYSE:MRK) took this path a year ago when it forged a partnership with Endocyte, Inc. (NASDAQ:ECYT). The big pharmaceutical company paid $120 million upfront and could pay up to $880 million more if certain milestones are met with Endocyte’s star product, vintafolide.

Vintafolide received orphan drug status in March 2012 in Europe. The drug is currently in a phase 3 clinical trial targeting platinum-resistant ovarian cancer and is in a phase 2 trial focusing on non-small-cell lung cancer.

Merck & Co., Inc. (NYSE:MRK)‘s possible $1 billion payout could prove to be a good investment if Wedbush analyst Gregory Wade is right. Wade estimates that vintafolide could hit peak sales in Europe of $400 million per year if approved later this year. He thinks another $500 million could be added to that annual total if the drug also receives approval in the U.S.

3. Thinking small
While Merck struck a big deal with Endocyte, smaller arrangements are more common. Pfizer Inc. (NYSE:PFE), for example, licensed small biotech Repligen‘s spinal muscular atrophy program earlier this year. Under the terms of the agreement, Pfizer Inc. (NYSE:PFE) paid $5 million upfront with potential future milestone payments up to $65 million. Repligen’s RG3039 drug has received orphan designations in both the U.S. and Europe.

Pfizer took the “thinking small” approach back in 2009 also. The big drugmaker inked a deal then with Protalix BioTherapeutics Inc. (NYSEAMEX:PLX) for rights to Gaucher disease drug Elelyso for $60 million upfront and up to $55 million in milestone payments. Pfizer and Protalix BioTherapeutics Inc. (NYSEAMEX:PLX) gained FDA approval for the drug in May 2012.

Just a few weeks ago, AbbVie Inc (NYSE:ABBV) threw a twist into this approach. Rather than buy rights for an orphan drug from a small biotech, the big pharma did the opposite. In March, small biotech Receptos licensed an experimental drug targeting orphan disease eosinophilic esophagitis from AbbVie Inc (NYSE:ABBV).

Rare opportunity
Big pharma companies appear likely to continue scaling up investments in drugs targeting orphan diseases. This hopefully will translate to better care for patients suffering from these rare diseases. Shareholders of the large pharmaceutical companies should profit from this focus. Investors in smaller biotechs that attract the interest of these bigger companies benefit also. The orphan drug market presents a win/win/win proposition. That’s rare.

The article 3 Ways Big Pharma Is Seizing This Rare Opportunity originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.